Navigation Links
Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations
Date:11/3/2009

KALAMAZOO, Mich., Nov. 3 /PRNewswire/ -- Tolera Therapeutics, Inc., announced it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) for its lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a novel biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection, and ultimate failure, of transplanted organs. Organ transplantation is often the only viable treatment for many end-stage organ diseases.

"We are extremely pleased with our progress toward bringing TOL101 to the clinic," commented John J. Puisis, President and CEO of Tolera. "This action marks an important development milestone as the company continues its drive to address the patient's need for safer and more effective immune suppression therapy. Current industry practices and pipelines offer limited and incomplete solutions to advance patient care and meet this critical need. Pending acceptance by the FDA, we intend to conduct clinical studies starting in 2010."

Tolera also announced the appointment of Leslie O'Toole to lead its clinical operations as Director, Clinical Programs. O'Toole brings over 20 years of industry experience with 16 years focusing on clinical research management. Mr. Puisis added "We're excited about adding Leslie to our dynamic team. Her depth of clinical research experience adds an important operating aspect to the organization and positions us for continued success." Prior to joining the company, O'Toole was Director, Project Management at Clinimetrics, a full service contract research organization where she was involved in over 35 studies researching drugs in numerous indications with a primary focus in oncology and immunology.

About Tolera Therapeutics: Tolera Therapeutics is a Kalamazoo, Michigan based biotechnology company and
'/>"/>

SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
5. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
11. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 BioStructures, LLC, a privately held ... milestone of 4,000 implantations of Signafuse® Bioactive Bone ... early 2014 as a bone void filler indicated ... This is a distinguished status among recently cleared ... new synthetic products have received clearance with a ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. ... developing and commercializing products for the treatment of cancer, ... announces that it has closed a $1,000,000 unit offering ... of 16,666,667 units of the Company at a price ... one common share and one common share purchase warrant.  ...
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... Powell, former,President and Chief Operating Officer of SurModics ... Corporation., Under Powell,s guidance, SurModics developed medical ... commercialize products.,Powell joined SurModics in 1987 as the ... company,s transition from a diagnostics kit,manufacturer to a ...
... July 29 SCOLR Pharma, Inc.,(Amex: DDD ) ... on Thursday, August 7, 2008, at 8:30 a.m. Eastern. ... host a conference call at 11:30,a.m. Eastern, to discuss ... participate in the,conference call by dialing +1 888 680 ...
... VOLC ), a leading manufacturer and developer ... Coherence,Tomography (OCT) products designed to enhance the diagnosis ... announced that it will,report its operating results for ... 2008 on Tuesday, August 5., The company ...
Cached Biology Technology:James C. Powell Joins Nerites Board of Directors 2SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern 2Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... worth celebrating. But for many in the South, the ... scatter and search for mates isn't one of them. ... of termites become more conspicuous, researchers with the Agricultural ... could someday knock down large numbers of Formosan subterranean ...
... imaging technologies allow physicians to visualize more of the ... not previously seen, but seeing more may have little ... , The study included 198 patients with suspected pulmonary ... multidetector CT (MDCT) examination; 100 patients had a single-detector ...
... the first active vaccine that can significantly delay and possibly ... is similar to mad cow disease. The new findings, published ... platform for the development of a vaccine to prevent a ... called prions. , Although no cure for these diseases -- ...
Cached Biology News:Fungus Effective Against Winged Termites 2Newer imaging techniques may lead to over-treatment 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3
... The Poly-Caspases FLICA Apoptosis Detection Kit contains ... a carboxyfluorescein (FAM) derivative of valylalanylaspartic acid ... of caspase activity. When added to ... probe enters each cell and covalently binds ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
Biology Products: